AEM vs NEU

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

NEU exhibits strong fundamental health with a Piotroski F-Score of 7/9 and robust liquidity, but it is currently trading at a significant premium to its deterministic value. The current price of $675.62 far exceeds both the Graham Number ($430.75) and the growth-based Intrinsic Value ($306.46). While profitability remains high with an ROE of 25.27%, the company is facing a growth contraction with negative YoY revenue and earnings growth. Consequently, the stock appears overvalued despite its operational quality.